Tarsier Pharma Announces Successful Type C Meeting with FDA for TRS01 in Noninfectious Uveitis

Agreement on registrational program's primary and key secondary Endpoint to reflect TRS01 positive risk/benefit profile for patients with noninfectious uveitis and uveitic glaucoma TRS01 has the potential to be the first line treatment option for noninfectious uveitis and specifically...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Tags: TRI PDT Source Type: news